Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Pyrotinib in HER2+ Early Breast Cancer
NCT06001086Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, pyrotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Nov 2023; status: recruiting.
02
Drugs
disitamab vedotinpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06001086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001086.